1. Home
  2. LGI vs NTHI Comparison

LGI vs NTHI Comparison

Compare LGI & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

LGI

Lazard Global Total Return and Income Fund

N/A

Current Price

$17.79

Market Cap

226.3M

Sector

N/A

ML Signal

N/A

NTHI

NeOnc Technologies Holdings Inc.

N/A

Current Price

$9.41

Market Cap

243.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LGI
NTHI
Founded
2004
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
226.3M
243.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
LGI
NTHI
Price
$17.79
$9.41
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
63.9K
29.6K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
7.10%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.95
$3.20
52 Week High
$19.88
$16.00

Technical Indicators

Market Signals
Indicator
LGI
NTHI
Relative Strength Index (RSI) 31.08 47.10
Support Level $17.19 $8.29
Resistance Level $17.75 $10.52
Average True Range (ATR) 0.30 0.60
MACD -0.22 -0.07
Stochastic Oscillator 5.26 20.98

Price Performance

Historical Comparison
LGI
NTHI

About LGI Lazard Global Total Return and Income Fund

Lazard Global Total Return & Inc Fd Inc is a United States-based diversified, closed-end management investment company. Its investment objective is total return consisting of capital appreciation and income. The fund's portfolio of investments consists of different sector investments such as consumer staples, financials, consumer discretionary, healthcare, materials, sovereign debt and others.

About NTHI NeOnc Technologies Holdings Inc.

NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA).

Share on Social Networks: